Supriya Lifescience has made a stellar debut on its listing day. With prices settling at Rs. 425 and Rs. 421, respectively on the BSE and NSE as against the issue price of Rs 274 per share. This is a premium of 55 percent.
Market sentiment has improved and GMP that Supriya Lifescience commanded also hinted at a premium listing. Other favourables for the company have been attractive valuations, strong financial track record with majority of the revenue from exports, robust return ratios among others.
The issue of Supriya that ran between December 16-20 has received an overwhelming response of over 71 times subscription. The issue has been a mix of OFS and fresh equity issuance totalling to Rs 700 crore.
There has been a general consensus that the stock shall see list at a premium of over 50%.
Abhay Doshi, Founder at UnlistedArena.com is quoted as saying in a leading publication, "Supriya Life Sciences has diverse offering in therapeutic segments offering 38 APIs in the segment. The company has export oriented operations which generates over 75 per cent of its revenue. On the operational front, there is visible growth in top and bottom line as the revenue grew over 22.78 per cent, EBITDA over 62 per cent and PAT grew over 68 per cent from FY20 to FY21."